

Jay M Sosenko

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5843740/publications.pdf>

Version: 2024-02-01

81
papers

8,416
citations

134610

34
h-index

71088

80
g-index

81
all docs

81
docs citations

81
times ranked

8141
citing authors

#	ARTICLE	IF	CITATIONS
1	Do-It-Yourself Diabetes Management: Perspectives of a Patient, a Physician, and an Ethicist. <i>Clinical Diabetes</i> , 2022, 40, 70-74.	1.2	1
2	HOMA2-B enhances assessment of type 1 diabetes risk among TrialNet Pathway to Prevention participants. <i>Diabetologia</i> , 2022, 65, 88-100.	2.9	2
3	Index60 Identifies Individuals at Appreciable Risk for Stage 3 Among an Autoantibody-Positive Population With Normal 2-Hour Glucose Levels: Implications for Current Staging Criteria of Type 1 Diabetes. <i>Diabetes Care</i> , 2022, 45, 311-318.	4.3	11
4	Oral Glucose Tolerance Test Measures of First-phase Insulin Response and Their Predictive Ability for Type 1 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e3273-e3280.	1.8	3
5	Index60 as an additional diagnostic criterion for type 1 diabetes. <i>Diabetologia</i> , 2021, 64, 836-844.	2.9	13
6	<i>TCF7L2</i> Genetic Variants Do Not Influence Insulin Sensitivity or Secretion Indices in Autoantibody-Positive Individuals at Risk for Type 1 Diabetes. <i>Diabetes Care</i> , 2021, 44, 2039-2044.	4.3	0
7	Time to Peak Glucose and Peak C-Peptide During the Progression to Type 1 Diabetes in the Diabetes Prevention Trial and TrialNet Cohorts. <i>Diabetes Care</i> , 2021, 44, 2329-2336.	4.3	5
8	The Deterrence of Rapid Metabolic Decline Within 3 Months After Teplizumab Treatment in Individuals at High Risk for Type 1 Diabetes. <i>Diabetes</i> , 2021, 70, 2922-2931.	0.3	11
9	Baseline Assessment of Circulating MicroRNAs Near Diagnosis of Type 1 Diabetes Predicts Future Stimulated Insulin Secretion. <i>Diabetes</i> , 2021, 70, 638-651.	0.3	9
10	The risk of progression to type 1 diabetes is highly variable in individuals with multiple autoantibodies following screening. <i>Diabetologia</i> , 2020, 63, 588-596.	2.9	58
11	Single Islet Autoantibody at Diagnosis of Clinical Type 1 Diabetes is Associated With Older Age and Insulin Resistance. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 1629-1640.	1.8	15
12	One-Hour Oral Glucose Tolerance Tests for the Prediction and Diagnostic Surveillance of Type 1 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e4094-e4101.	1.8	17
13	The Pathological Evolution of Glucose Response Curves During the Progression to Type 1 Diabetes in the TrialNet Pathway to Prevention Study. <i>Diabetes Care</i> , 2020, 43, 2668-2674.	4.3	9
14	The Effect of Ethnicity in the Rate of Beta-Cell Functional Loss in the First 3 Years After Type 1 Diabetes Diagnosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e4393-e4406.	1.8	4
15	Provider-Guided Emergency Support for Persons Living With Type 1 Diabetes During Hurricanes Harvey, Irma, and Maria. <i>Disaster Medicine and Public Health Preparedness</i> , 2020, 14, 150-154.	0.7	2
16	Early and late C-peptide responses during oral glucose tolerance testing are oppositely predictive of type 1 diabetes in autoantibody-positive individuals. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 997-1000.	2.2	5
17	The Association Between Heart Rate and Glycemic Status in the National Health and Nutrition Examination Surveys. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e858-e870.	1.8	4
18	Slowed Metabolic Decline After 1 Year of Oral Insulin Treatment Among Individuals at High Risk for Type 1 Diabetes in the Diabetes Prevention Trial—Type 1 (DPT-1) and TrialNet Oral Insulin Prevention Trials. <i>Diabetes</i> , 2020, 69, 1827-1832.	0.3	23

#	ARTICLE	IF	CITATIONS
19	The Influence of Type 2 Diabetes-associated Factors on Type 1 Diabetes. <i>Diabetes Care</i> , 2019, 42, 1357-1364.	4.3	30
20	Associations of HbA1c with the timing of C-peptide responses during the oral glucose tolerance test at the diagnosis of type 1 diabetes. <i>Pediatric Diabetes</i> , 2019, 20, 408-413.	1.2	3
21	Predicting progression to type 1 diabetes from ages 3 to 6 in islet autoantibody positive TEDDY children. <i>Pediatric Diabetes</i> , 2019, 20, 263-270.	1.2	31
22	<i>TCF7L2</i> Genetic Variants Contribute to Phenotypic Heterogeneity of Type 1 Diabetes. <i>Diabetes Care</i> , 2018, 41, 311-317.	4.3	51
23	The shape of the glucose concentration curve during an oral glucose tolerance test predicts risk for type 1 diabetes. <i>Diabetologia</i> , 2018, 61, 84-92.	2.9	27
24	The Effect of Age on the Progression and Severity of Type 1 Diabetes: Potential Effects on Disease Mechanisms. <i>Current Diabetes Reports</i> , 2018, 18, 115.	1.7	32
25	Transcription Factor 7-Like 2 (<i>TCF7L2</i>) Gene Polymorphism and Progression From Single to Multiple Autoantibody Positivity in Individuals at Risk for Type 1 Diabetes. <i>Diabetes Care</i> , 2018, 41, 2480-2486.	4.3	23
26	A Type 1 Diabetes Genetic Risk Score Predicts Progression of Islet Autoimmunity and Development of Type 1 Diabetes in Individuals at Risk. <i>Diabetes Care</i> , 2018, 41, 1887-1894.	4.3	104
27	The influence of body mass index and age on C-peptide at the diagnosis of type 1 diabetes in children who participated in the diabetes prevention trial-type 1. <i>Pediatric Diabetes</i> , 2018, 19, 403-409.	1.2	17
28	β Cell dysfunction exists more than 5 years before type 1 diabetes diagnosis. <i>JCI Insight</i> , 2018, 3, .	2.3	62
29	The Use of Electrochemiluminescence Assays to Predict Autoantibody and Glycemic Progression Toward Type 1 Diabetes in Individuals with Single Autoantibodies. <i>Diabetes Technology and Therapeutics</i> , 2017, 19, 183-187.	2.4	21
30	Association of serum microRNAs with islet autoimmunity, disease progression and metabolic impairment in relatives at risk of type 1 diabetes. <i>Diabetologia</i> , 2017, 60, 1409-1422.	2.9	61
31	Can Non-HLA Single Nucleotide Polymorphisms Help Stratify Risk in TrialNet Relatives at Risk for Type 1 Diabetes?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 2873-2880.	1.8	20
32	Diabetic Neuropathy: A Position Statement by the American Diabetes Association. <i>Diabetes Care</i> , 2017, 40, 136-154.	4.3	1,452
33	Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis. <i>Diabetes</i> , 2017, 66, 241-255.	0.3	454
34	Dysglycemia and Index60 as Prediagnostic End Points for Type 1 Diabetes Prevention Trials. <i>Diabetes Care</i> , 2017, 40, 1494-1499.	4.3	28
35	Impact of Age and Antibody Type on Progression From Single to Multiple Autoantibodies in Type 1 Diabetes Relatives. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 2881-2886.	1.8	35
36	Elevations in the Fasting Serum Proinsulin-to-C-Peptide Ratio Precede the Onset of Type 1 Diabetes. <i>Diabetes Care</i> , 2016, 39, 1519-1526.	4.3	106

#	ARTICLE	IF	CITATIONS
37	The relationship between BMI and insulin resistance and progression from single to multiple autoantibody positivity and type 1 diabetes among TrialNet Pathway to Prevention participants. <i>Diabetologia</i> , 2016, 59, 1186-1195.	2.9	36
38	ECL-IAA and ECL-GADA Can Identify High-Risk Single Autoantibody-Positive Relatives in the TrialNet Pathway to Prevention Study. <i>Diabetes Technology and Therapeutics</i> , 2016, 18, 410-414.	2.4	25
39	Do Electrochemiluminescence Assays Improve Prediction of Time to Type 1 Diabetes in Autoantibody-Positive TrialNet Subjects?. <i>Diabetes Care</i> , 2016, 39, 1738-1744.	4.3	19
40	Staging the progression to type 1 diabetes with prediagnostic markers. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2016, 23, 297-305.	1.2	12
41	HLA-DRB1*15:01-DQA1*01:02-DQB1*06:02 Haplotype Protects Autoantibody-Positive Relatives From Type 1 Diabetes Throughout the Stages of Disease Progression. <i>Diabetes</i> , 2016, 65, 1109-1119.	0.3	48
42	The Development and Utility of a Novel Scale That Quantifies the Glycemic Progression Toward Type 1 Diabetes Over 6 Months. <i>Diabetes Care</i> , 2015, 38, 940-942.	4.3	14
43	β^2 Cell death and dysfunction during type 1 diabetes development in at-risk individuals. <i>Journal of Clinical Investigation</i> , 2015, 125, 1163-1173.	3.9	121
44	Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association. <i>Diabetes Care</i> , 2015, 38, 1964-1974.	4.3	690
45	The Development, Validation, and Utility of the Diabetes Prevention Trial-Type 1 Risk Score (DPtrs). <i>Current Diabetes Reports</i> , 2015, 15, 49.	1.7	14
46	A New Approach for Diagnosing Type 1 Diabetes in Autoantibody-Positive Individuals Based on Prediction and Natural History. <i>Diabetes Care</i> , 2015, 38, 271-276.	4.3	59
47	Use of the Diabetes Prevention Trial-Type 1 Risk Score (DPtrs) for Improving the Accuracy of the Risk Classification of Type 1 Diabetes. <i>Diabetes Care</i> , 2014, 37, 979-984.	4.3	37
48	The Prediction of Type 1 Diabetes by Multiple Autoantibody Levels and Their Incorporation Into an Autoantibody Risk Score in Relatives of Type 1 Diabetic Patients. <i>Diabetes Care</i> , 2013, 36, 2615-2620.	4.3	100
49	The Evolution of Type 1 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 2491.	3.8	10
50	Acceleration of the Loss of the First-Phase Insulin Response During the Progression to Type 1 Diabetes in Diabetes Prevention Trial-Type 1 Participants. <i>Diabetes</i> , 2013, 62, 4179-4183.	0.3	67
51	The Application of the Diabetes Prevention Trial-Type 1 Risk Score for Identifying a Preclinical State of Type 1 Diabetes. <i>Diabetes Care</i> , 2012, 35, 1552-1555.	4.3	33
52	Fall in C-Peptide During First 2 Years From Diagnosis. <i>Diabetes</i> , 2012, 61, 2066-2073.	0.3	270
53	The Metabolic Progression to Type 1 Diabetes as Indicated by Serial Oral Glucose Tolerance Testing in the Diabetes Prevention Trial-Type 1. <i>Diabetes</i> , 2012, 61, 1331-1337.	0.3	52
54	Prognostic Accuracy of Immunologic and Metabolic Markers for Type 1 Diabetes in a High-Risk Population. <i>Diabetes Care</i> , 2012, 35, 1975-1980.	4.3	34

#	ARTICLE	IF	CITATIONS
55	Zinc Transporter-8 Autoantibodies Improve Prediction of Type 1 Diabetes in Relatives Positive for the Standard Biochemical Autoantibodies. <i>Diabetes Care</i> , 2012, 35, 1213-1218.	4.3	84
56	A comparison of the baseline metabolic profiles between Diabetes Prevention Trial-Type 1 and TrialNet Natural History Study participants. <i>Pediatric Diabetes</i> , 2011, 12, 85-90.	1.2	12
57	A Longitudinal Study of GAD65 and ICA512 Autoantibodies During the Progression to Type 1 Diabetes in Diabetes Prevention Trial-Type 1 (DPT-1) Participants. <i>Diabetes Care</i> , 2011, 34, 2435-2437.	4.3	29
58	Validation of the Diabetes Prevention Trial-Type 1 Risk Score in the TrialNet Natural History Study. <i>Diabetes Care</i> , 2011, 34, 1785-1787.	4.3	42
59	Development of Autoantibodies in the TrialNet Natural History Study. <i>Diabetes Care</i> , 2011, 34, 1897-1901.	4.3	55
60	Prognostic Performance of Metabolic Indexes in Predicting Onset of Type 1 Diabetes. <i>Diabetes Care</i> , 2010, 33, 2508-2513.	4.3	48
61	Glucose Excursions Between States of Glycemia With Progression to Type 1 Diabetes in the Diabetes Prevention Trial-Type 1 (DPT-1). <i>Diabetes</i> , 2010, 59, 2386-2389.	0.3	32
62	Progression to Diabetes in Relatives of Type 1 Diabetic Patients: Mechanisms and Mode of Onset. <i>Diabetes</i> , 2010, 59, 679-685.	0.3	120
63	Trends of Earlier and Later Responses of C-peptide to Oral Glucose Challenges With Progression to Type 1 Diabetes in Diabetes Prevention Trial-Type 1 Participants. <i>Diabetes Care</i> , 2010, 33, 620-625.	4.3	58
64	Pancreatic Islet Autoantibodies as Predictors of Type 1 Diabetes in the Diabetes Prevention Trial-Type 1. <i>Diabetes Care</i> , 2009, 32, 2269-2274.	4.3	224
65	Incident Dysglycemia and Progression to Type 1 Diabetes Among Participants in the Diabetes Prevention Trial-Type 1. <i>Diabetes Care</i> , 2009, 32, 1603-1607.	4.3	59
66	The prevalence of diabetic neuropathy according to ethnicity. <i>Current Diabetes Reports</i> , 2009, 9, 435-439.	1.7	17
67	The TrialNet Natural History Study of the Development of Type 1 Diabetes: objectives, design, and initial results. <i>Pediatric Diabetes</i> , 2009, 10, 97-104.	1.2	160
68	A Risk Score for Type 1 Diabetes Derived From Autoantibody-Positive Participants in the Diabetes Prevention Trial-Type 1. <i>Diabetes Care</i> , 2008, 31, 528-533.	4.3	98
69	Glucose and C-Peptide Changes in the Perionset Period of Type 1 Diabetes in the Diabetes Prevention Trial-Type 1. <i>Diabetes Care</i> , 2008, 31, 2188-2192.	4.3	68
70	Prevention of type 1 diabetes: the time has come. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2008, 4, 334-343.	2.9	41
71	Increasing the Accuracy of Oral Glucose Tolerance Testing and Extending Its Application to Individuals With Normal Glucose Tolerance for the Prediction of Type 1 Diabetes: The Diabetes Prevention Trial-Type 1. <i>Diabetes Care</i> , 2007, 30, 38-42.	4.3	61
72	Patterns of Metabolic Progression to Type 1 Diabetes in the Diabetes Prevention Trial-Type 1. <i>Diabetes Care</i> , 2006, 29, 643-649.	4.3	150

#	ARTICLE	IF	CITATIONS
73	Diabetic Neuropathies: A statement by the American Diabetes Association. Diabetes Care, 2005, 28, 956-962.	4.3	1,599
74	Sensory Function and Albumin Excretion According to Diagnostic Criteria for Diabetes. Diabetes Care, 2004, 27, 1716-1720.	4.3	5
75	Diabetic Somatic Neuropathies. Diabetes Care, 2004, 27, 1458-1486.	4.3	756
76	Albuminuria in Recent-Onset Type 2 Diabetes: The Strong Heart Study. Diabetes Care, 2002, 25, 1078-1084.	4.3	16
77	The epidemiology of neuropathic foot ulcers in individuals with diabetes. Current Diabetes Reports, 2002, 2, 477-481.	1.7	4
78	NBME examination part I as a predictor of clinical and ABIM certifying examination performances. Journal of General Internal Medicine, 1993, 8, 86-88.	1.3	33
79	Comparison of Quantitative Sensory-Threshold Measures for Their Association With Foot Ulceration in Diabetic Patients. Diabetes Care, 1990, 13, 1057-1061.	4.3	146
80	Neurofunctional Testing for the Detection of Diabetic Peripheral Neuropathy. Archives of Internal Medicine, 1987, 147, 1741.	4.3	27
81	Body stature as a risk factor for diabetic sensory neuropathy. American Journal of Medicine, 1986, 80, 1031-1034.	0.6	82